Login / Signup

Momelotinib for myelofibrosis: our 14 years of experience with 100 clinical trial patients and recent FDA approval.

Ayalew TefferiAnimesh Pardanani
Published in: Blood cancer journal (2024)
Keyphrases
  • clinical trial
  • end stage renal disease
  • newly diagnosed
  • ejection fraction
  • chronic kidney disease
  • prognostic factors
  • randomized controlled trial
  • study protocol
  • patient reported outcomes
  • patient reported